Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
1-15 of 4506 results
Boehringer Ingelheim partners with TARGET to progress NASH research
TARGET PharmaSolutions announced that Boehringer Ingelheim International has entered into a multi-year strategic partnership for TARGET-NASH.
Drug Research > Drug Discovery & Development > News
Alnylam, Vir to jointly advance RNAi therapeutics for infectious diseases
Alnylam Pharmaceuticals has announced an exclusive licensing agreement with Vir Biotechnology for the development and commercialization of RNAi therapeutics for infectious diseases, including chronic hepatitis B virus (HBV) infection.
Drug Research > Drug Discovery & Development > News
Takeda, HemoShear collaborate to develop drugs for liver diseases
By PBR Staff Writer
Takeda has collaborated with HemoShear Therapeutics to discover and develop novel therapeutics for liver diseases such as nonalcoholic steatohepatitis (NASH).
Drug Research > Drug Discovery & Development > News
Moleculin to collaborate with University of Bergen for immune stimulation drug
Moleculin Biotech has entered into an agreement to collaborate with the University of Bergen to expand research on inhibition of brain metastasis by its pre-clinical drug WP1066 and its ability to increase immune system response to cancer and suppression of tumor cell proliferation and survival.
Drug Research > Drug Discovery & Development > News
Moffitt researchers discover new targets for approved cancer drug
A team of researchers at Moffitt Cancer Center used cellular drug screening, functional proteomics and computer-based modeling to determine whether drugs with well-known targets may be repurposed for use against other biological targets.
Drug Research > Drug Discovery & Development > News
PanOptica secures $11m to advance clinical development novel topical anti-VEGF eye drop
PanOptica a private biopharmaceutical company focused on developing innovative ophthalmology therapies, announced that it has secured $11m in a series B financing.
Drug Research > Drug Discovery & Development > News
Visterra closes $46.7m series C financing to advance pipeline of precision antibody-based biological medicines
Visterra has completed a series C financing round raising a total of $46.7m, including a new extension totaling $23.6m.
Drug Research > Drug Discovery & Development > News
Ligand to acquire Crystal Bioscience
Ligand Pharmaceuticals has announced the signing of a merger agreement whereby Ligand will acquire Crystal, a leader in avian genetics and the generation of fully-human therapeutic antibodies.
Drug Research > Drug Discovery & Development > News
Recursion Pharmaceuticals raises $60m to industrialize drug discovery using artificial intelligence
Recursion Pharmaceuticals, a biotechnology company that combines innovative biological science with artificial intelligence to discover new therapeutics at scale, is announcing its $60m series B financing led by Data Collective (DCVC).
Drug Research > Drug Discovery & Development > News
Amgen, CytomX partner to develop immuno-oncology drugs
By PBR Staff Writer
Amgen has partnered with CytomX Therapeutics to develop and commercialize new immuno-oncology drugs.
Drug Research > Drug Discovery & Development > News
Immatics secures funding to develop T-cell receptor based immunotherapies
By PBR Staff Writer
Immatics has secured $58m of funding for the development of T-cell receptor based immunotherapies.
Drug Research > Drug Discovery & Development > News
X-Chem further expands collaboration with Bayer to discover novel medicines
X-Chem and Bayer have further expanded their drug discovery collaboration across multiple therapeutic areas and target classes.
Drug Research > Drug Discovery & Development > News
Gilead Sciences completes acquisition of Kite Pharma
Gilead Sciences has announced the completion of the previously announced transaction for Dodgers Merger Sub a wholly-owned subsidiary of Gilead (purchaser), to acquire Kite Pharma, for $180 per share, net to the seller in cash, without interest, or approximately $11.9bn in the aggregate.
Drug Research > Drug Discovery & Development > News
US HHS accelerates development of first Ebola vaccines and drugs
The US Department of Health & Human Services (HHS) has accelerated the development of first Ebola vaccines and drugs.
Drug Research > Drug Discovery & Development > News
1-15 of 4506 results